BOSTON ( TheStreet) -- Welcome to TheStreet's 2012 FDA Drug Approval Prediction Contest.Your challenge: Correctly pick the approval decisions to be made by the U.S. Food and Drug Administration on 17 drugs between January and April. The person(s) with the most accurate predictions will receive a hearty congratulations, a mention in a future column and bragging rights as the best FDA drug-approval prognosticator of 2012.
Feb. 14: BioSante Pharmaceuticals' (BPAX) Bio-T-Gel for hypogonadism.
Feb. 17: Corcept Therapeutics' (CORT - Get Report) Corlux for Cushing's sydrome.
Feb. 26: Columbia Labs' (CBRX) Prochieve for reduction of risk of preterm birth.
March 6: Discovery Labs' (DSCO) Surfaxin for respiratory distress syndrome.
March 6: Astex Pharmaceuticals' (ASTX) Dacogen for acute myeloid leukemia.
March 7: Neurogesx' (NGSX) Qutenza for HIV-related nerve pain.
March 8: Roche and Curis' (CRIS - Get Report) vismodegib for basal cell carcinoma.
March 26: MAP Pharmaceuticals' (MAPP) Levadex for migraines.
March 27: Affymax's (AFFY) peginesatide for anemia due to chronic kidney disease.
March 28: Chelsea Therapeutics' (CHTP) Northera for orthostatic hypotension.
April 17: Vivus' (VVUS - Get Report) Qnexa for obesity.
April 18: Vertex Pharmaceuticals' (VRTX) Kalydeco for cystic fibrosis
April 24: Cell Therapeutics' (CTIC - Get Report) pixantrone for non-Hodgkin's lymphoma
April 26: Amgen's (AMGN) Xgeva for prevention or delay of spread of prostate cancer to bone.
April 27: Vivus' (VVUS - Get Report) avanafil for erectile dysfunction. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.